Bernhard Kulzer declares the following potential conflicts of interest: Advisory boards: Bayer, Becton Dickinson, Berlin Chemie, Novo Nordisk, Sanofi, Roche. Lectures, study projects (FIDAM): Abbott, AstraZeneca, Bayer, Becton Dickinson, Berlin Chemie, Dexcom, Novo Nordisk, Sanofi, Roche. Jens Aberle declares the following conflicts of interest: Advisory boards and lecturer for: Astra Zeneca, Berlin-Chemie, Boehringer-Ingelheim, Eli Lilly & Co, Novo Nordisk, Roche Diabetes Care. Institutional research funding: Astra Zeneca. Thomas Haak declares the following conflicts of interest: Advisory boards: MSD, AstraZeneca, Roche, Abbott. Paid lecturing or training: Diabetes Academy Bad Mergentheim e.V., Abbott. Research project/implementation of clinical trials: Boehringer Ingelheim, Principal Investigator, AstraZeneca, Abbott REPLACE study. Matthias Kaltheuner declares that he has no conflicts of interest. Jens Kröger declares the following potential conflicts of interest: Advisory boards: Abbott GmbH, AstraZeneca, BD, MSD, Novo-Nordisk, Lilly; lectures, study projects: Abbott GmbH & Co. KG, AstraZeneca, Bayer vital, Boehringer-Ingelheim, Boehringer-Mannheim, BERLIN-CHEMIE, Dexcom, Glaxo, Medtronic, MSD, Novo-Nordisk, Lilly, Roche, Sanofi-Aventis, Vitalaire; Shareholdings, shares: none; volunteer work: Chairman of the Board diabetesDE – German Diabetes Aid Rüdiger Landgraf declares the following potential conflicts of interest: Advisory boards: Lilly Deutschland, Novo Nordisk Pharma; lecture fees: AstraZeneca, Bayer Vital, Berlin Chemie, Lilly Deutschland, Novo Nordisk Pharma. Other activities: Trustee of the German Diabetes Foundation, member of the steering group for the development and updating of the National Healthcare Guidelines on Diabetes. Monika Kellerer declares the following potential conflicts of interest: research support (RCT): AstraZeneca; Lilly; Novo Nordisk; membership in advisory bodies: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Sanofi. Lecture fees: Bayer Boehringer Ingelheim, BMS, Novartis, MSD, Novo Nordisk.